Index RUT
P/E -
EPS (ttm) -1.22
Insider Own 20.51%
Shs Outstand 105.65M
Perf Week -1.62%
Market Cap 764.96M
Forward P/E -
EPS next Y -1.14
Insider Trans -0.05%
Shs Float 83.99M
Perf Month 17.23%
Income -115.16M
PEG -
EPS next Q -0.26
Inst Own 86.36%
Short Float 10.62%
Perf Quarter 34.57%
Sales 0.00M
P/S -
EPS this Y 44.76%
Inst Trans 20.75%
Short Ratio 7.48
Perf Half Y 49.18%
Book/sh 3.42
P/B 2.13
EPS next Y -16.54%
ROA -36.04%
Short Interest 8.92M
Perf Year 203.33%
Cash/sh 3.51
P/C 2.07
EPS next 5Y 38.60%
ROE -42.20%
52W Range 2.05 - 8.40
Perf YTD 60.35%
Dividend Est. -
P/FCF -
EPS past 5Y -29.69%
ROI -29.61%
52W High -13.33%
Beta 1.23
Dividend TTM -
Quick Ratio 21.81
Sales past 5Y 0.00%
Gross Margin -
52W Low 255.99%
ATR (14) 0.33
Dividend Ex-Date -
Current Ratio 21.81
EPS Y/Y TTM 38.27%
Oper. Margin 0.00%
RSI (14) 54.32
Volatility 3.13% 4.87%
Employees 71
Debt/Eq 0.08
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 15.50
Option/Short Yes / Yes
LT Debt/Eq 0.08
EPS Q/Q 51.36%
Payout -
Rel Volume 0.58
Prev Close 7.32
Sales Surprise -
EPS Surprise -0.22%
Sales Q/Q -
Earnings Aug 12 BMO
Avg Volume 1.19M
Price 7.28
SMA20 -0.60%
SMA50 8.76%
SMA200 27.83%
Trades
Volume 686,141
Change -0.55%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-24 Upgrade
JP Morgan
Neutral → Overweight
$11
Dec-21-23 Upgrade
BofA Securities
Neutral → Buy
$4 → $6
Oct-30-23 Initiated
Wells Fargo
Overweight
$11
May-26-23 Downgrade
BofA Securities
Buy → Neutral
$8 → $3
May-25-23 Downgrade
JP Morgan
Overweight → Neutral
$19 → $9
Sep-16-22 Initiated
Jefferies
Buy
$12
Sep-09-22 Initiated
BTIG Research
Buy
$15
Nov-30-21 Initiated
H.C. Wainwright
Buy
$40
Sep-23-21 Initiated
Cantor Fitzgerald
Overweight
$40
Jan-26-21 Initiated
Needham
Buy
$37
Aug-18-20 Initiated
JP Morgan
Overweight
$33
Aug-18-20 Initiated
Cowen
Outperform
Aug-18-20 Initiated
BofA Securities
Buy
$33
Show Previous Ratings
Oct-21-24 08:00PM
Oct-16-24 08:00AM
Oct-15-24 08:00AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
08:00AM
Loading…
Sep-03-24 08:00AM
Aug-29-24 08:00AM
Aug-16-24 04:05PM
Aug-12-24 08:00AM
Aug-05-24 08:00AM
Jul-16-24 04:05PM
Jul-11-24 06:09PM
(GlobeNewswire) +8.53%
+11.15%
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
05:00PM
Loading…
Jun-25-24 05:00PM
05:00PM
Jun-24-24 06:35AM
Jun-18-24 08:00AM
Jun-17-24 04:05PM
Jun-07-24 09:40AM
Jun-05-24 11:04PM
(GlobeNewswire) +13.36%
-13.25%
10:57AM
09:55AM
04:45AM
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM
Loading…
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Love Douglas PRESIDENT AND CEO Oct 30 '24 Option Exercise 1.85 114,449 211,742 310,570 Nov 01 04:15 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Oct 15 '24 Option Exercise 1.85 5,408 10,005 76,773 Oct 17 05:09 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Oct 15 '24 Sale 7.41 5,408 40,073 71,365 Oct 17 05:09 PM Yednock Ted Officer Oct 15 '24 Proposed Sale 7.41 5,408 40,073 Oct 15 02:03 PM Carson William H. Director Oct 01 '24 Buy 5.97 3,200 19,104 22,400 Oct 02 04:15 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Sep 19 '24 Sale 7.10 4,500 31,950 0 Sep 20 04:30 PM Yednock Ted Officer Sep 19 '24 Proposed Sale 7.10 4,500 31,950 Sep 19 12:32 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Sep 12 '24 Sale 6.16 5,500 33,880 4,500 Sep 16 04:30 PM Yednock Ted Officer Sep 12 '24 Proposed Sale 6.16 5,500 33,880 Sep 12 10:24 AM Yednock Ted EVP & CHIEF INNOVATION OFFICER Sep 05 '24 Sale 5.64 5,500 31,020 10,000 Sep 06 04:30 PM Yednock Ted Officer Sep 05 '24 Proposed Sale 5.64 5,500 31,020 Sep 05 10:15 AM Carson William H. Director Sep 03 '24 Buy 5.48 3,200 17,536 19,200 Sep 04 04:34 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Aug 29 '24 Sale 5.95 5,500 32,725 15,500 Aug 30 06:00 PM Yednock Ted Officer Aug 29 '24 Proposed Sale 5.95 5,500 32,725 Aug 29 02:08 PM Carson William H. Director Aug 01 '24 Buy 6.24 3,200 19,968 16,000 Aug 05 07:53 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Jul 15 '24 Sale 6.02 784 4,720 94,622 Jul 17 04:49 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Jul 15 '24 Sale 6.03 1,104 6,657 86,468 Jul 17 04:48 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Jul 15 '24 Sale 6.02 1,106 6,658 71,365 Jul 17 04:46 PM Carson William H. Director Jul 01 '24 Buy 5.00 3,200 16,000 12,800 Jul 02 05:43 PM Carson William H. Director Jun 03 '24 Buy 4.83 3,200 15,459 9,600 Jun 05 04:23 PM Carson William H. Director May 01 '24 Buy 4.68 3,200 14,982 6,400 May 03 04:15 PM Carson William H. Director Apr 08 '24 Buy 6.07 3,200 19,411 3,200 Apr 10 07:17 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 20 '24 Sale 5.53 2,593 14,339 82,058 Feb 21 04:31 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 20 '24 Sale 5.51 2,604 14,348 72,471 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 20 '24 Sale 5.48 1,951 10,691 85,641 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 12 '24 Sale 5.53 1,349 7,460 48,592 Feb 14 07:59 PM Love Douglas PRESIDENT AND CEO Feb 12 '24 Sale 5.54 5,782 32,032 196,121 Feb 14 07:56 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 12 '24 Sale 5.54 1,809 10,022 45,651 Feb 14 07:54 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 12 '24 Sale 5.54 1,810 10,027 36,075 Feb 14 07:52 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Option Exercise 1.63 21,000 34,176 21,000 Dec 29 04:12 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Sale 4.52 21,000 94,966 0 Dec 29 04:12 PM Satter Muneer A Director Dec 26 '23 Buy 2.88 350,000 1,008,000 7,406,024 Dec 28 04:30 PM
Index -
P/E -
EPS (ttm) -2.11
Insider Own 51.52%
Shs Outstand 27.61M
Perf Week 38.95%
Market Cap 60.30M
Forward P/E -
EPS next Y -0.58
Insider Trans 0.00%
Shs Float 21.31M
Perf Month 81.94%
Income -65.53M
PEG -
EPS next Q -0.25
Inst Own 14.59%
Short Float 0.49%
Perf Quarter 43.99%
Sales 2.36M
P/S 25.55
EPS this Y 54.80%
Inst Trans 4.21%
Short Ratio 0.50
Perf Half Y 11.86%
Book/sh 0.76
P/B 1.74
EPS next Y 54.11%
ROA -71.92%
Short Interest 0.10M
Perf Year -42.75%
Cash/sh 1.64
P/C 0.80
EPS next 5Y -
ROE -130.03%
52W Range 0.49 - 2.89
Perf YTD 140.00%
Dividend Est. -
P/FCF -
EPS past 5Y -44.91%
ROI -159.90%
52W High -54.39%
Beta -0.20
Dividend TTM -
Quick Ratio 2.02
Sales past 5Y 0.00%
Gross Margin 23.76%
52W Low 169.39%
ATR (14) 0.12
Dividend Ex-Date -
Current Ratio 2.02
EPS Y/Y TTM 31.42%
Oper. Margin -2830.04%
RSI (14) 71.68
Volatility 16.24% 12.11%
Employees 73
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -2780.27%
Recom 1.33
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.23
EPS Q/Q 65.78%
Payout -
Rel Volume 1.43
Prev Close 1.27
Sales Surprise -92.14%
EPS Surprise -4.35%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 209.40K
Price 1.32
SMA20 43.73%
SMA50 55.91%
SMA200 45.92%
Trades
Volume 299,798
Change 3.94%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated
Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated
H.C. Wainwright
Buy
$36
Nov-16-21 Initiated
Raymond James
Outperform
$31
Nov-16-21 Initiated
Morgan Stanley
Overweight
$32
Nov-16-21 Initiated
Guggenheim
Buy
$40
Nov-16-21 Initiated
Cowen
Outperform
Oct-30-24 09:01AM
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
04:05PM
Loading…
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Loading…
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
07:30AM
Loading…
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite